ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 626

The Impact of the Interaction Between Human Leukocyte Antigen Alleles and Obesity on Psoriatic Arthritis Risk

Lihi Eder1, Fatima Abji1, Cheryl Rosen2, Proton Rahman3, Vinod Chandran1 and Dafna D. Gladman1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: human leukocyte antigens (HLA), obesity, psoriatic arthritis and risk

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Human Leukocyte Antigen (HLA) class I alleles and obesity are risk factors for psoriatic arthritis (PsA). We aimed to assess whether there is an interaction between HLA risk alleles for PsA and obesity in susceptibility to PsA.

Methods: The study comprised two parts: 1) a case-only design that included patients with early PsA (<2 years) from 2 PsA cohorts, 2) a case-control design in which patients with early PsA were compared to those with psoriasis alone (PsC). Body Mass Index (BMI) at the first visit was stratified to normal (<25), overweight (25≤BMI<30) and obese (≥30). HLA genotyping was performed by sequence-specific oligonucleotide probes. The following alleles that were independently associated with PsA were analyzed: HLA-B*08, B*18, B*27, B*38, B*39 and C*06. Due to low frequency and similar structure, the effect of HLA-B*08, B*18, B*39 and B*38 was assessed in conjunction (termed “combined HLA-B alleles”). The interaction between obesity and HLA alleles was assessed by comparing the distribution of the various alleles across the three BMI categories in patients with PsA using trend test (case-only design). The interaction between HLA alleles and obesity was further investigated (case-control design) by assessing a departure from multiplicative combined effect of risk using logistic regression analysis after adjusting for age and sex and by assessing a departure from additivity by calculating the attributable proportion (AP).

Results: 637 Caucasians patients were analyzed (262 PsA, 375 PsC). Obesity was more frequent in patients with PsA compared to those with PsC (p=0.005). In addition, HLA-B*27 (p=0.0001) and the combined HLA-B alleles (p=0.03) were associated with PsA vs. PsC. A differential distribution of HLA-B alleles was observed across the 3 BMI categories in patients with PsA (case-only design) suggesting an interaction. The frequency of B*27 was higher in patients with normal weight compared to those with higher BMI (ptrend=0.005). In contrast, PsA patients who carried one of the combined HLA-B alleles tended to be heavier (ptrend=0.03). Similar findings were observed in the case-control analysis (Figure 1). A multiplicative interaction was found for the combined effect of B*27 and obesity in logistic regression analysis (OR 0.1 p=0.01) as well as for the joint effect of combined HLA-B alleles and obesity (OR 2.7 p=0.03). A significant additive interaction of combined HLA-B alleles and obesity was found with the proportion of risk due to additive interaction (AP) of 0.62 (95% CI 0.38, 0.93, p=0.0001). No interaction was found between obesity and HLA-C*06 allele.

Conclusion: An interaction was found between HLA-B alleles and obesity in PsA risk thus the effect of obesity on PsA risk may depend on the presence of HLA-B alleles.


Disclosure:

L. Eder,
None;

F. Abji,
None;

C. Rosen,
None;

P. Rahman,
None;

V. Chandran,
None;

D. D. Gladman,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-the-interaction-between-human-leukocyte-antigen-alleles-and-obesity-on-psoriatic-arthritis-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology